ABSTRACT
Benign prostatic hyperplasia (BPH) and the lower urinary tract symptoms (LUTS) associated with the condition are becoming increasingly prevalent as the Western male population ages and healthcare provision worldwide improves. The need for new and improved treatments for the condition is therefore ongoing and likely to increase.
